Search Results - "Fragola, V"

HIV-1 coreceptor switch during 2 years of structured treatment interruptions by Baroncelli, S., Galluzzo, C. M., Andreotti, M., Pirillo, M. F., Fragola, V., Weimer, L. E., Giuliano, M., Vella, S., Palmisano, L.

“…The purpose of this investigation was to determine the impact on human immunodeficiency virus (HIV) tropism of uncontrolled virus exposure during 2 years of…”
Get full text

Long-term Maraviroc Therapy and Limited Side Effects in an HIV-1 Experienced Patient: Six Years of Antiretroviral Observation by Cirioni, O, Weimer, L E, Fragola, V, Giacometti, A, Sozio, F

Get full text

A Reduction Grade of Lipodystrophy and Limited Side Effects after HAART Regimen with Raltegravir, Lamivudine, Darunavir and Ritonavir in an HIV-1 Infected Patient after Six Years of Antiretroviral Therapy by Degli Antoni, A, Weimer, L E, Fragola, V, Giacometti, A, Sozio, F

“…HIV-associated lipodystrophy commonly presents with fat loss in the face, buttocks, arms and legs, hypocomplementaemia, glomerulonephritis, and autoimmune…”
Get full text

A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation by Cirioni, O, Weimer, L E, Fragola, V, Giacometti, A, Ancarani, F, Maracci, M, Gabrielli, E, Marchionni, E, Pirillo, M F, Vella, S

“…In this case report, we examine the impact of a simplified two-drug highly active antiretroviral therapy (HAART) regimen of raltegravir and lamivudine in a…”
Get full text

Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors by Bucciardini, R, D'Ettorre, G, Baroncelli, S, Ceccarelli, G, Parruti, G, Weimer, L E, Fragola, V, Galluzzo, C M, Pirillo, M F, Lucattini, S, Bellagamba, R, Francisci, D, Ladisa, N, Degli Antoni, A, Guaraldi, G, Manconi, P E, Vullo, V, Preziosi, R, Cirioni, O, Verucchi, G, Floridia, M

“…We evaluated rates and determinants of virological failure in triple-class experienced patients receiving raltegravir-based regimens from a national…”
Get more information

A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use by Degli Antoni, A, Weimer, L E, Manfredi, R, Fragola, V, Ferrari, C

“…The use of new antiretroviral drugs in HIV infection is particularly important in patients with intolerance or resistance to other antiretroviral agents…”
Get more information

Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report by Cirioni, O, Weimer, L E, Fragola, V, Giacometti, A, Gabrielli, E, Marchionni, E, Massella, M, Barchiesi, F

“…Sustained increase of serum creatine phosphokinase (CPK) concentrations and muscle abnormalities have been reported in patients taking raltegravir (RAL). In…”
Get more information

The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy by Palmisano, L, Giuliano, M, Galluzzo, CM, Amici, R, Andreotti, M, Weimer, LE, Pirillo, MF, Fragola, V, Bucciardini, R, Vella, S

“…Objectives The aim of the study was to determine the modifications of the mutational archive in proviral HIV‐1 DNA occurring during 24 months of intermittent…”
Get full text

Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia by SPIRITO, P, RAPEZZI, C, CANNATA, D, MAGNANI, B, VECCHIO, C, AUTORE, C, BRUZZI, P, BELLONE, P, ORTOLANI, P, FRAGOLA, P. V, CHIARELLA, F, ZONI-BERISSO, M, BRANZI, A

“…In the early 1980s, studies performed in highly selected referral patients with hypertrophic cardiomyopathy reported a strong association between the presence…”
Get full text

Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy by Massella, M, Ivanovic, J, Bellagamba, R, De Vita, R, Fracasso, L, Tozzi, V, Fragola, V, Rizzica, M, Narciso, P

“…This study aims to assess direct cost of reconstructive interventions with facial fillers for treatment of HIV (human immunodeficiency virus)-associated facial…”
Get full text

Natural history of cardiac involvement in myotonic dystrophy : Correlation with CTG repeats by ANTONINI, G, GIUBILEI, F, MAMMARELLA, A, AMICUCCI, P, FIORELLI, M, GRAGNANI, F, MORINO, S, CESCHIN, V, FRAGOLA, P. V, GENNARELLI, M

“…The authors prospectively studied the natural course of cardiac involvement and its relationship to cytosine-thymine-guanine (CTG) expansion in 50 patients…”
Get full text

ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era by Bucciardini, R, Murri, R, Guarinieri, M, Starace, F, Martini, M, Vatrella, A, Cafaro, L, Fantoni, M, Grisetti, R, Monforte, A d'Arminio, Fragola, V, Arcieri, R, Del Borgo, C, Tramarin, A, Massella, M, Lorenzetti, D, Vella, S

“…To design a Health-related Quality of Life (HRQoL) instrument for HIV-infected people in the era of highly active antiretroviral therapy (HAART). The…”
Get full text

Cardiac involvement in myotonic dystrophy by Fragola, Pietro V., Luzi, Mario, Calò, Leonardo, Antonini, Giovanni, Borzi, Mauro, Frongillo, Doriana, Cannata, Dario

“…A report on the course of heart disease in myotonic dystrophy is presented. There is no certain way to predict appearance or progression of cardiac involvement…”
Get full text

T20QoL : an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy by Bucciardini, R

“…Evaluates the impact of health-related quality of life (HRQoL) enfuvirtide-based (ENF-based) salvage regimens of treatment-experienced HIV patients, in an…”
Get full text

A factor analytic study of the Italian National Institute of Health Quality of Life - Core Evaluation Form (ISSQoL-CEF) by Lauriola, M, Murri, R, Massella, M, Mirra, M, Donnini, S, Fragola, V, Ivanovic, J, Pavoni, M, Mancini, G, Bucciardini, R

“…The Italian National Institute of Health Quality of Life - Core Evaluation Form (ISSQoL-CEF) is a specific questionnaire measuring health-related quality of…”
Get full text

HIV‐related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/µL): an analysis of 338 clinical events from a randomized clinical trial by Floridia, M, Fragola, V, Galluzzo, CM, Giannini, G, Pirillo, MF, Andreotti, M, Tomino, C, Vella for the ISS‐IP1 Study Group, S

“…Background AIDS defining events occur infrequently in the presence of CD4 counts above 200 cells/µL. It is, however, uncertain for most of the AIDS defining…”
Get full text

Risk factors and occurrence of rash in HIV‐positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside‐experienced patients with very low CD4 levels (<50 cells/mμL) by Floridia, M, Bucciardini, R, Fragola, V, Galluzzo, CM, Giannini, G, Pirillo, MF, Amici, R, Andreotti, M, Ricciardulli, D, Tomino, C, Vella, S

“…Background Most of the studies evaluating rash in HIV‐positive patients have focused on nonnucleoside reverse transcriptase inhibitors (NNRTI), particularly…”
Get full text

Left ventricular myocardial function in myotonic dystrophy by Badano, Luigi, Autore, Camillo, Fragola, Pietro V., Picelli, Antonella, Antonini, Giovanni, Vichi, Rossana, Cannata, Dario

“…Myotonic dystrophy is an autosomal dominant disease affecting many organ systems, including the heart. Abnormalities of the cardiac conduction system are a…”
Get full text

Meta-analysis of Two Randomized Controlled Trials Comparing Combined Zidovudine and Didanosine Therapy With Combined Zidovudine, Didanosine, and Nevirapine Therapy in Patients With HIV by Raboud, J. M., Rae, S., Vella, S., Harrigan, P. R., Bucciardini, R., Fragola, V., Ricciardulli, D., Montaner, J. S. G.

Get full text

Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment by Vella, Stefano, Galluzzo, M.C, Giannini, G, Pirillo, M.F, Andreotti, M, Tomino, C, Fragola, V, Bucciardini, R, Ricciardulli, D, Binelli, A, Weimer, L.E, Floridia, M

“…Some studies on untreated patients have shown a general correlation between plasma HIV copy number and plasma infectivity in in vitro models. Recent…”
Get full text